$32.38
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 2,475 full-time employees. The company went IPO on 2014-04-11. The company develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. The company markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. The company has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
Country

US

CEO

Mr. Jack Bendheim

IPO date

2014

Employees

2,475

ISIN

US71742Q1067

Key stats

Open

$32.47

Volume

172.80K

Market cap

$1.32B

Prev. close

$32.38

Impl / hst vl

-

Open interest

$0.00

$32.32

Day’s Range

$33.23

$28.25

52W Range

$60.08

Valuation

50
Valuation score
Fairly Valued
P/E
14.11
P/S
0.90
P/B
3.71
Current ratio
3.17
Debt / Equity
1.88
ROE
29.49%
Gross margin
32.77%
Income growth
-12.51%
FCF growth
-89.22

Jun

24

Dividends

The last payment date was Jun 24, 2026

Div. per Share

$0.12

Div. Yield

0.37%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Hold

The average rating from top 5 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$43.35
The top 7 analysts forecasts that 12-month price may increase by 33.88%, with a low of $38.38 and a high of $51.45
$38.38
Low
$43.35
Avg
$51.45
High
Current price

Earnings

Q1 ‘26 revenue
$383.54M
Q1 ‘26 net income
$24.02M
Revenue
Net income
Previous EPS
$0.87
Estimate EPS
$0.73
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply